Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LGND files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsLigand announces $550M convertible notes offering, amends credit facility to lower EBITDA covenants
Filed June 22, 2026 · Period ending June 22, 2026 · ~1 min read
Key Changes
-
high
Ligand proposes $550M convertible senior notes due 2031 (plus up to $82.5M greenshoe) in private placement to qualified institutional buyers; terms including conversion price and interest rate not disclosed.
Item 8.01 — Other Events verify on EDGAR → -
high
Credit agreement amended to permit convertible offering and reduce minimum EBITDA covenant to $100M for four quarters ending June 2026 through March 2027, then $150M thereafter, suggesting near-term earnings pressure.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
Proceeds will fund convertible note hedges (partially offset by warrant sales), up to $75M in concurrent share repurchases from note buyers at market price, and general corporate purposes including potential acquisitions.
Exhibit 99.1 view on EDGAR → -
medium
Ligand entering convertible note hedge transactions to reduce dilution from conversions, but issuing warrants that could dilute shareholders if stock exceeds warrant strike price.
Exhibit 99.1 view on EDGAR → -
medium
Counterparties establishing hedges may purchase shares and trade derivatives around pricing, potentially supporting stock price and resulting in higher effective conversion price for notes.
Exhibit 99.1 view on EDGAR →
Summary
Ligand Pharmaceuticals announced a $550 million convertible senior notes offering due 2031, with a 15% greenshoe option that could bring total proceeds to $632.5 million.
The company simultaneously amended its credit facility to permit the offering and, notably, reduced its minimum consolidated EBITDA covenant from $150 million to $100 million for the four quarters ending June 2026 through March 2027 before stepping back up. This covenant relief suggests Ligand anticipates near-term profitability challenges requiring financial flexibility.
The company plans to use proceeds for convertible note hedges (partially offset by warrant sales), up to $75 million in concurrent share repurchases from note buyers, and general corporate purposes including potential acquisitions beyond the previously announced Xoma Royalty acquisition. The concurrent repurchase program and counterparty hedging activity could support the stock price around pricing, potentially resulting in a more favorable conversion price. However, the warrant transactions introduce potential dilution if the stock appreciates significantly. The combination of covenant relief and substantial new debt financing indicates Ligand is managing near-term financial constraints while positioning for strategic investments.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the Company issued a press release announcing the proposed offering of $550 million aggregate principal amount of convertible senior notes due 2031 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).
Ligand is proposing to issue $550 million in convertible senior notes maturing in 2031 through a private placement to qualified institutional buyers under Rule 144A. The filing does not disclose the conversion price, interest rate, or intended use of proceeds.
Added in current filing · verify on EDGAR →
The Company also announced its intent to grant the initial purchasers of the Notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the Notes are issued, up to an additional $82.5 million aggregate principal amount of Notes.
The initial purchasers have a 13-day option to buy an additional $82.5 million of notes, which would bring the total offering size to $632.5 million if fully exercised. This is a standard greenshoe provision representing 15% of the base offering.
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
on June 22, 2026, Ligand Pharmaceuticals Incorporated (the “Company”), as borrower, entered into a Consent and Fourth Amendment to Credit Agreement (the “Fourth Amendment”) with certain of the Company’s subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein) party thereto, and Citibank, N.A., as Administrative Agent (as defined therein), which amends that certain Credit Agreement, dated as of October 12, 2023
Ligand entered into a fourth amendment to its existing credit agreement with Citibank as administrative agent. The amendment permits the company to issue convertible notes in a planned offering and modifies financial covenant requirements. This is the fourth amendment to the credit facility originally established in October 2023.
Event · Exhibit 99.1
Ligand announces proposed $550M convertible senior notes offering due 2031 to enhance financial flexibility and fund share repurchases.
Added in current filing · view on EDGAR →
Ligand expects to use a portion of the net proceeds from the offering to pay the cost of the convertible note hedge transactions described below (after such cost is partially offset by the proceeds to Ligand from the sale of the warrants in the warrant transactions described below). In addition, Ligand expects to use up to $75 million of the net proceeds from the offering to repurchase shares of its common stock from certain purchasers of the notes in privately negotiated transactions, as described below. Ligand intends to use the remaining net proceeds from the offering for general corporate purposes including investing in complementary businesses, companies, products and technologies, although Ligand has no present commitments or agreements to do so beyond its previously announced agreement to acquire Xoma Royalty Corporation.
Ligand will use proceeds to fund convertible note hedge transactions (partially offset by warrant sale proceeds) and up to $75 million for concurrent share repurchases from note buyers. Remaining proceeds are earmarked for general corporate purposes including potential acquisitions, with the previously announced Xoma Royalty Corporation acquisition specifically mentioned.
Added in current filing · view on EDGAR →
In connection with the pricing of the notes, Ligand expects to enter into convertible note hedge transactions (the “convertible note hedge transactions”) with one or more of the initial purchasers or their respective affiliates and/or other financial institutions (the “option counterparties”). Ligand also expects to enter into warrant transactions (the “warrant transactions”) with the option counterparties, pursuant to which Ligand will issue warrants to purchase common stock (the “warrants”) to such option counterparties. The convertible note hedge transactions are expected generally to reduce the potential dilution to Ligand’s common stock upon any conversion of notes and/or offset any cash payments Ligand is required to make in excess of the principal amount of converted notes, as the case may be. However, the warrant transactions could separately have a dilutive effect on Ligand’s common stock to the extent that the market price per share of common stock exceeds the strike price of the warrants.
Ligand will enter into convertible note hedge transactions to reduce dilution from note conversions and offset cash payments above principal. Simultaneously, Ligand will issue warrants to the same counterparties, which could dilute shareholders if the stock price exceeds the warrant strike price. These transactions are designed to manage the dilutive impact of the convertible notes.
Added in current filing · view on EDGAR →
In addition, Ligand expects to use up to $75 million of the net proceeds from the offering to repurchase shares of its common stock from certain purchasers of the notes in privately negotiated transactions effected through one of the initial purchasers or an affiliate thereof concurrently with the pricing of the notes. The price per share of Ligand’s common stock repurchased in such transactions is expected to equal the last reported price per share of Ligand’s common stock as of the date of the pricing of the notes. These repurchases could increase (or reduce the size of any decrease in) the market price of Ligand’s common stock prior to, concurrently with or shortly after the pricing of the notes, and could result in a higher effective conversion price for the notes.
Ligand will use up to $75 million of offering proceeds to repurchase shares from note buyers in concurrent privately negotiated transactions at the last reported stock price on pricing date. The company acknowledges these repurchases could support the stock price and result in a higher effective conversion price for the notes.
Added in current filing · view on EDGAR →
In connection with establishing their initial hedges of the convertible note hedge transactions and the warrant transactions, Ligand expects the option counterparties or their respective affiliates to enter into various derivative transactions with respect to Ligand’s common stock and/or purchase shares of Ligand’s common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Ligand’s common stock or the notes at that time.
The company discloses that counterparties establishing hedges will likely trade derivatives and purchase shares around the pricing date, which could affect the stock price. Additionally, ongoing hedge adjustments throughout the notes' life could impact both stock and note prices, particularly during conversion observation periods.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 22, 2026 · How we verify